Accès gratuit
Med Sci (Paris)
Volume 19, Numéro 1, Janvier 2003
Page(s) 63 - 69
Section M/S Revues
Publié en ligne 15 janvier 2003
  1. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203–34. [Google Scholar]
  2. Sutton BJ, Gould HJ. The human IgE network. Nature 1993; 366: 421–8. [Google Scholar]
  3. Kinet JP. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931–72. [Google Scholar]
  4. Kinet JP. Atopic allergy and other hypersensitivities. Curr Opin Immunol 1999; 11: 603–5. [Google Scholar]
  5. Hagan P, Blumenthal D, Dunn AJ, Simpson B, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349: 243–5. [Google Scholar]
  6. Gounni AS, Lamkhioued B, Ochiai K, et al. Highaffinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994; 367: 183–6. [Google Scholar]
  7. Jankovic D, Kullberg MC, Dombrowicz D, et al. FcεRI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology. J Immunol 1997; 159: 1868–75. [Google Scholar]
  8. Blank U, Ra C, Miller L, White K, Metzger H, Kinet, JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989; 337: 187–9. [Google Scholar]
  9. Garman, SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its highaffinity receptor FcεRIa. Nature 2000; 406: 259–66. [Google Scholar]
  10. Lin S, Cicala C, Scharenberg AM, Kinet JP. The FcεRIb subunit functions as an amplifier of FcεRIgmediated cell activation signals. Cell 1996; 85: 985–95. [Google Scholar]
  11. Donnadieu E, Jouvin MH, Kinet JP. A second amplifier function for the allergyassociated FcεRI-b subunit. Immunity 2000; 12: 515–23. [Google Scholar]
  12. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergyassociated FcRb is a molecular amplifier of IgEand IgG-mediated in vivo responses. Immunity 1998; 8: 517–29. [Google Scholar]
  13. Nissim A, Jouvin MH, Eshhar Z. Mapping of the high affinity Fce receptor binding site to the third constant region domain of IgE. EMBO J 1991; 10: 101–7. [Google Scholar]
  14. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623–32. [Google Scholar]
  15. Henry AJ, Cook JP, McDonnell JM, et al. Participation of the Nterminal region of Cε3 in the binding of human IgE to its high-affinity receptor FcεRI. Biochemistry 1997; 36: 15568–78. [Google Scholar]
  16. Hakimi J, Seals C, Kondas JA, Danho W, Kochan J. The a subunit of the human IgE receptor is sufficient for high affinity IgE binding. J Biol Chem 1990; 265: 22079–81. [Google Scholar]
  17. Blank U, Ra CS, Kinet JP. Characterization of truncated a chain products from human, rat, and mouse high affinity receptor for immunoglobulin E. J Biol Chem 1991; 266: 2639–46. [Google Scholar]
  18. Letourneur O, Sechi S, Willette-Brown J, Robertson MW, Kinet JP. Glycosylation of human truncated FcεRI a chain is necessary for efficient folding in the endoplasmic reticulum. J Biol Chem 1995; 270: 8249–56. [Google Scholar]
  19. Cook JP, Henry AJ, McDonnell JM, Owens RJ, Sutton BJ, Gould HJ. Identification of contact residues in the IgE binding site of human FcεRIa. Biochemistry 1997; 36: 15579–88. [Google Scholar]
  20. Garman SC, Kinet JP, Jardetzky TS. Crystal structure of the human high-affinity IgE receptor. Cell 1998; 7: 951–61. [Google Scholar]
  21. Mendoza G, Metzger H. Distribution and valency of receptor for IgE on rodent mast cells and related tumour cells. Nature 1976; 264: 548–50. [Google Scholar]
  22. Sechi S, Roller PP, Willette- Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem 1996; 271: 19256–63. [Google Scholar]
  23. Wurzburg BA, Garman SC, Jardetzky TS. Structure of the human IgE-Fc Cε3-C e- 4 reveals conformational flexibility in the antibody effector domains. Immunity 2000; 13: 375–85. [Google Scholar]
  24. Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie I, Hogarth PM. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 1999; 6: 437–42. [Google Scholar]
  25. Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human FcγRIIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution. EMBO J 1999; 18: 1095–103. [Google Scholar]
  26. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000; 406: 267–73. [Google Scholar]
  27. Radaev S, Motyka S, Fridman WH., Sautes- Fridman C, Sun PD. The structure of a human type III Fcg receptor in complex with Fc. J Biol Chem 2001; 276: 16469–77. [Google Scholar]
  28. Ring J, Kramer U, Schafer T, Behrendt H. Why are allergies increasing? Curr Opin Immunol 2001; 13: 701–8. [Google Scholar]
  29. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308–12. [Google Scholar]
  30. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157–62. [Google Scholar]
  31. Boulet P, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835–40. [Google Scholar]
  32. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828–34. [Google Scholar]
  33. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N Engl J Med 1999; 341: 1966–73. [Google Scholar]
  34. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–61. [Google Scholar]
  35. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–90. [Google Scholar]
  36. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110–21. [Google Scholar]
  37. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253–9. [Google Scholar]
  38. Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160: 1023–7. [Google Scholar]
  39. Borkowski TA, Jouvin MH, Lin SY, Kinet JP. Minimal requirements for IgEmediated regulation of surface Fc epsilon RI. J Immunol 2001; 167: 1290–6. [Google Scholar]
  40. Saini SS, MacGlashan DW, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FcεRI a surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162: 5624–30. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.